paclitaxel + doxorubicin + cisplatin + cyclophosphamide

This is a **four-drug chemotherapy combination regimen** used primarily in the treatment of advanced solid tumors, particularly **breast cancer** and **ovarian cancer**. The regimen combines four distinct cytotoxic agents with complementary mechanisms of action: - **Paclitaxel (Taxol)**: A taxane that stabilizes microtubules and prevents cancer cell division - **Doxorubicin (Adriamycin)**: An anthracycline that intercalates DNA and inhibits topoisomerase II, causing DNA damage - **Cisplatin**: A platinum-based agent that forms DNA cross-links and prevents DNA replication - **Cyclophosphamide (Cytoxan)**: An alkylating agent that damages DNA during the resting phase of cells The combination has been studied in high-dose chemotherapy protocols with peripheral blood progenitor cell rescue for high-risk primary breast cancer and responsive metastatic disease. Clinical trials have demonstrated the feasibility of this intensive regimen, with dose-limiting toxicity primarily consisting of reversible sensory neuropathy. The regimen has shown promising response rates in both breast and ovarian cancer settings, though careful attention to drug sequencing and administration is required to optimize efficacy and minimize toxicity.

Other names

TAP-CTAPCACT with paclitaxelpaclitaxel-doxorubicin-cyclophosphamide-cisplatin